Tvardi Therapeutics (NASDAQ:TVRD) Downgraded to "Market Perform" Rating by Raymond James Financial

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) was downgraded by Raymond James Financial from an "outperform" rating to a "market perform" rating in a note issued to investors on Tuesday,Briefing.com Automated Import reports.Get Tvardi Therapeutics alerts:Other equities analysts have also recently issued reports about the stock. Barclays set a $5.00 target price on shares of Tvardi Therapeutics and gave the company a "negative" rating in a research note on Monday. Weiss Ratings reiterated a "sell (e)" rating on shares of Tvardi Therapeutics in a research note on Saturday, September 27th. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday. Piper Sandler cut shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday. Finally, BTIG Research cut their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a "buy" rating for the company in a research note on Monday. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $55.50.View Our Latest Report on Tvardi TherapeuticsTvardi Therapeutics Stock Down 83.9%Shares of Tvardi Therapeutics stock opened at $6.69 on Tuesday. The business has a fifty day moving average price of $31.63. Tvardi Therapeutics has a 1-year low of $5.65 and a 1-year high of $43.65. Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%. Institutional Investors Weigh In On Tvardi TherapeuticsSeveral institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at $43,000. Headlands Technologies LLC bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $80,000. New York State Common Retirement Fund bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $92,000. Finally, Bank of America Corp DE bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $399,000. Institutional investors own 44.66% of the company's stock. Tvardi Therapeutics Company Profile (Get Free Report)Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.See AlsoFive stocks we like better than Tvardi Therapeutics3 Tickers Leading a Meme Stock RevivalFastenal Stock Pulls Back in October—Is It Time to Buy FAST?Best Stocks Under $5.00Why Congress Is Buying Intuitive Surgical Ahead of EarningsStock Splits, Do They Really Impact Investors?FICO’s Big Dip Could Be the Best Buying Chance of the YearThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Tvardi Therapeutics Right Now?Before you consider Tvardi Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.While Tvardi Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here